Unveiling the first GIP and GLP-1 medication for Chronic Weight Management and Type 2 Diabetes

Introduction

Learn about the obesity as a chronic disease, the role of GIP and GLP-1 in obesity and type 2 diabetes and the mechanism of action of Mounjaro as first-in-class medication for chronic weight management and type 2 diabetes.

Objectives

-Learn about obesity as a chronic disease which is a public health issue across the globe and specially in KSA
-Better understanding of the Pathophysiology of T2D/obesity, the related metabolic adaption and the role of GIP and GLP-1 receptors.
-Unveiling the mechanism of action of Mounjaro as the first-and-only treatment activating both the GIP and GLP-1 receptors to treat T2D and chronic weigh management.
-Understand the data from the clinical trials related to efficacy and safety of Mounjaro in T2D and chronic weigh management.